Difference between revisions of "Editorial Board"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m (Text replacement - "thumb|upright=0.4|center]]" to "frameless|upright=0.4|center]]")
Line 4: Line 4:
 
{| class="wikitable" style="text-align:center; width: 60%;"
 
{| class="wikitable" style="text-align:center; width: 60%;"
 
|-
 
|-
−
|style="background-color:#F0F0F0; width: 42%;"|[[File:PeterYang.jpg|thumb|upright=0.4|center]]
+
|style="background-color:#F0F0F0; width: 42%;"|[[File:PeterYang.jpg|frameless|upright=0.4|center]]
 
|<big>[[User:PeterYang|Peter C. Yang, MD]]<br>Boston, MA</big><br>Twitter: [https://twitter.com/Hem_Onc Hem_Onc]
 
|<big>[[User:PeterYang|Peter C. Yang, MD]]<br>Boston, MA</big><br>Twitter: [https://twitter.com/Hem_Onc Hem_Onc]
 
|-
 
|-
Line 12: Line 12:
 
{| class="wikitable"  style="text-align:center; width: 60%;"
 
{| class="wikitable"  style="text-align:center; width: 60%;"
 
|-
 
|-
−
|style="background-color:#F0F0F0; width: 42%;"|[[File:Warner Jeremy2 compact.jpg|thumb|upright=0.4|center]]
+
|style="background-color:#F0F0F0; width: 42%;"|[[File:Warner Jeremy2 compact.jpg|frameless|upright=0.4|center]]
 
|<big>[[User:Jwarner|Jeremy L. Warner, MD, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/Hemoncwarner Hemoncwarner]<br>[https://www.linkedin.com/in/jeremy-warner-39001512/ LinkedIn]
 
|<big>[[User:Jwarner|Jeremy L. Warner, MD, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/Hemoncwarner Hemoncwarner]<br>[https://www.linkedin.com/in/jeremy-warner-39001512/ LinkedIn]
 
|-
 
|-
Line 21: Line 21:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Dermatologic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Dermatologic Oncology'''
 
|-
 
|-
−
|rowspan=4 style="background-color:#F0F0F0; width:25%;"|[[File:Bethbuchbinder.jpg|thumb|upright=0.4|center]]
+
|rowspan=4 style="background-color:#F0F0F0; width:25%;"|[[File:Bethbuchbinder.jpg|frameless|upright=0.4|center]]
 
|rowspan=4 style="width:35%"|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
 
|rowspan=4 style="width:35%"|<big>[[User:Bethbuchbinder|Elizabeth Buchbinder, MD]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/beth-buchbinder-2a9b994/ LinkedIn]
 
|style="background-color:#deebf7"|[[Basal cell carcinoma (BCC)]]
 
|style="background-color:#deebf7"|[[Basal cell carcinoma (BCC)]]
Line 33: Line 33:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gastrointestinal Oncology'''
 
|-
 
|-
−
|rowspan=8 style="background-color:#F0F0F0"|[[File:nkv.jpg|thumb|upright=0.4|center]]
+
|rowspan=8 style="background-color:#F0F0F0"|[[File:nkv.jpg|frameless|upright=0.4|center]]
 
|rowspan=8|<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
 
|rowspan=8|<big>[[User:Neetavenepalli|Neeta K. Venepalli, MD, MBA]]<br>Chicago, IL</big>
 
|style="background-color:#deebf7"|[[Anal cancer]]
 
|style="background-color:#deebf7"|[[Anal cancer]]
Line 53: Line 53:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Genitourinary Oncology'''
 
|-
 
|-
−
|rowspan=5 style="background-color:#F0F0F0"|[[File:aymen_elfiky.jpg|thumb|upright=0.4|center]]
+
|rowspan=5 style="background-color:#F0F0F0"|[[File:aymen_elfiky.jpg|frameless|upright=0.4|center]]
 
|rowspan=5|<big>[[User:Aymenelfiky|Aymen Elfiky, MD, MSc, MBA]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn]
 
|rowspan=5|<big>[[User:Aymenelfiky|Aymen Elfiky, MD, MSc, MBA]]<br>Boston, MA</big><br>[https://www.linkedin.com/in/aymen-elfiky-15420873/ LinkedIn]
 
|style="background-color:#deebf7"|[[Bladder cancer]]
 
|style="background-color:#deebf7"|[[Bladder cancer]]
Line 67: Line 67:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gynecologic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Gynecologic Oncology'''
 
|-
 
|-
−
|rowspan=3 style="background-color:#F0F0F0"|[[File:BrandonSeagle.jpg|thumb|upright=0.4|center]]
+
|rowspan=3 style="background-color:#F0F0F0"|[[File:BrandonSeagle.jpg|frameless|upright=0.4|center]]
 
|rowspan=3|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big>
 
|rowspan=3|<big>[[User:Blseagle|Brandon L. Seagle, MD, MS]]<br>Chicago, IL</big>
 
|style="background-color:#deebf7"|[[Cervical cancer]]
 
|style="background-color:#deebf7"|[[Cervical cancer]]
Line 77: Line 77:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Head & Neck Cancer'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Head & Neck Cancer'''
 
|-
 
|-
−
|rowspan=3 style="background-color:#F0F0F0"|[[File:Michaelgibson.jpg|thumb|upright=0.4|center]]
+
|rowspan=3 style="background-color:#F0F0F0"|[[File:Michaelgibson.jpg|frameless|upright=0.4|center]]
 
|rowspan=3|<big>[[User:Michaelgibson|Michael Gibson, MD, PhD]]<br>Nashville, TN</big>
 
|rowspan=3|<big>[[User:Michaelgibson|Michael Gibson, MD, PhD]]<br>Nashville, TN</big>
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
 
|style="background-color:#deebf7"|[[Head and neck cancer]]
Line 87: Line 87:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Neuro-Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Neuro-Oncology'''
 
|-
 
|-
−
|rowspan=6 style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|thumb|upright=0.4|center]]
+
|rowspan=6 style="background-color:#F0F0F0"|[[File:SeemaNagpal.jpg|frameless|upright=0.4|center]]
 
|rowspan=6|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big>
 
|rowspan=6|<big>[[User:Seemanagpal|Seema Nagpal, MD]]<br>Palo Alto, CA</big>
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
 
|style="background-color:#deebf7"|[[Anaplastic glioma]]
Line 103: Line 103:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Sarcoma'''
 
|-
 
|-
−
|rowspan=4 style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|thumb|upright=0.4|center]]
+
|rowspan=4 style="background-color:#F0F0F0"|[[File:jim_chen.jpeg|frameless|upright=0.4|center]]
 
|rowspan=4|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
 
|rowspan=4|<big>[[User:Jimchen|James L. Chen, MD, MS]]<br>Columbus, OH</big><br>[https://www.linkedin.com/in/jameschen777/ LinkedIn]
 
|style="background-color:#deebf7"|[[Ewing's sarcoma]]
 
|style="background-color:#deebf7"|[[Ewing's sarcoma]]
Line 115: Line 115:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Thoracic Oncology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#3182bd"|'''Thoracic Oncology'''
 
|-
 
|-
−
|rowspan=5 style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|thumb|upright=0.4|center]]
+
|rowspan=5 style="background-color:#F0F0F0"|[[File:TravisOsterman.jpg|frameless|upright=0.4|center]]
 
|rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
 
|rowspan=5|<big>[[User:Travisosterman|Travis Osterman, DO, MS]]<br>Nashville, TN</big><br>Twitter: [https://twitter.com/TravisOsterman TravisOsterman]<br>[https://www.linkedin.com/in/travis-osterman-1850b236/ LinkedIn]
 
|style="background-color:#deebf7"|[[Esophageal cancer]]
 
|style="background-color:#deebf7"|[[Esophageal cancer]]
Line 129: Line 129:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms and Myelodysplastic Syndromes'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Myeloproliferative Neoplasms and Myelodysplastic Syndromes'''
 
|-
 
|-
−
|rowspan=8 style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|thumb|upright=0.4|center]]
+
|rowspan=8 style="background-color:#F0F0F0"|[[File:Sanjay_mohan.png|frameless|upright=0.4|center]]
 
|rowspan=8|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big>
 
|rowspan=8|<big>[[User:Sanjaymohan|Sanjay R. Mohan, MD, MSCI]]<br>Nashville, TN</big>
 
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]]
 
|style="background-color:#fee0d2"|[[Chronic myelogenous leukemia]]
Line 149: Line 149:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Plasma Cell Dyscrasias'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#de2d26"|'''Plasma Cell Dyscrasias'''
 
|-
 
|-
−
|rowspan=4 style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|thumb|upright=0.4|center]]
+
|rowspan=4 style="background-color:#F0F0F0"|[[File:Headshot Cowan.jpg|frameless|upright=0.4|center]]
 
|rowspan=4|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn]
 
|rowspan=4|<big>[[User:Andrewc072|Andrew J. Cowan, MD]]<br>Seattle, WA</big><br>[https://www.linkedin.com/in/andrew-cowan-63b3a130/ LinkedIn]
 
|style="background-color:#fee0d2"|[[Multiple myeloma]]
 
|style="background-color:#fee0d2"|[[Multiple myeloma]]
Line 161: Line 161:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#756bb1"|'''Transplant'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#756bb1"|'''Transplant'''
 
|-
 
|-
−
|rowspan=4 style="background-color:#F0F0F0"|[[File:Arichall_400x400.jpg|thumb|upright=0.4|center]]
+
|rowspan=4 style="background-color:#F0F0F0"|[[File:Arichall_400x400.jpg|frameless|upright=0.4|center]]
 
|rowspan=4|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1]
 
|rowspan=4|<big>[[User:AricHallMD|Aric C. Hall, MD]]<br>Madison, WI</big><br>Twitter: [https://twitter.com/AricHall1 AricHall1]
 
|style="background-color:#efedf5"|[[Stem cell mobilization]]
 
|style="background-color:#efedf5"|[[Stem cell mobilization]]
Line 173: Line 173:
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Classical Hematology'''
 
!colspan="3" align="center" style="color:white; font-size:125%; background-color:#31a354"|'''Classical Hematology'''
 
|-
 
|-
−
|rowspan=6 style="background-color:#F0F0F0"|[[File:Shruti.jpg|thumb|upright=0.4|center]]
+
|rowspan=6 style="background-color:#F0F0F0"|[[File:Shruti.jpg|frameless|upright=0.4|center]]
 
|rowspan=6|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MD, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
 
|rowspan=6|<big>[[User:Shrutichaturvedi|Shruti Chaturvedi, MD, MSCI]]<br>Baltimore, MD</big><br>[https://www.linkedin.com/in/shruti-chaturvedi-bb83b126/ LinkedIn]
 
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
 
|style="background-color:#e5f5e0"|[[Aplastic anemia]]
Line 187: Line 187:
 
|style="background-color:#e5f5e0"|[[Cold agglutinin disease]]
 
|style="background-color:#e5f5e0"|[[Cold agglutinin disease]]
 
|-
 
|-
−
|rowspan=5 style="background-color:#F0F0F0"|[[File:Tillman_Benjamin-2.jpg|thumb|upright=0.4|center]]
+
|rowspan=5 style="background-color:#F0F0F0"|[[File:Tillman_Benjamin-2.jpg|frameless|upright=0.4|center]]
 
|rowspan=5|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big>
 
|rowspan=5|<big>[[User:Benjamintillman|Benjamin Tillman, MD]]<br>Nashville, TN</big>
 
|style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]
 
|style="background-color:#e5f5e0"|[[Hemophagocytic lymphohistiocytosis (HLH)]]

Revision as of 02:56, 12 January 2018

We have recently appointed an editorial board of clinical experts, organized primarily by disease focus. Many disease sites now have expert representation, but we are still looking for potential section or page editors. If you are interested, please feel free to contact us with any questions or inquiries, at [email protected].

Editor-in-Chief

PeterYang.jpg
 Peter C. Yang, MD
Boston, MA
Twitter: Hem_Onc

Deputy Editor

Warner Jeremy2 compact.jpg
 Jeremy L. Warner, MD, MS
Nashville, TN
Twitter: Hemoncwarner
LinkedIn

Section Editors

Dermatologic Oncology
Bethbuchbinder.jpg
 Elizabeth Buchbinder, MD
Boston, MA
LinkedIn 		Basal cell carcinoma (BCC)
Melanoma
Merkel cell carcinoma
Squamous cell carcinoma (SCC)
Gastrointestinal Oncology
Nkv.jpg
 Neeta K. Venepalli, MD, MBA
Chicago, IL 		Anal cancer
Colon cancer
Esophageal cancer
Gastric cancer
Gastrointestinal stromal tumor (GIST)
Hepatobiliary cancer
Pancreatic cancer
Rectal cancer
Genitourinary Oncology
Aymen elfiky.jpg
 Aymen Elfiky, MD, MSc, MBA
Boston, MA
LinkedIn 		Bladder cancer
Penile cancer
Prostate cancer
Renal cancer
Testicular cancer
Gynecologic Oncology
BrandonSeagle.jpg
 Brandon L. Seagle, MD, MS
Chicago, IL 		Cervical cancer
Ovarian cancer
Uterine cancer
Head & Neck Cancer
Michaelgibson.jpg
 Michael Gibson, MD, PhD
Nashville, TN 		Head and neck cancer
Nasopharyngeal carcinoma
Thyroid cancer
Neuro-Oncology
SeemaNagpal.jpg
 Seema Nagpal, MD
Palo Alto, CA 		Anaplastic glioma
CNS leukemia
CNS lymphoma
Glioblastoma
Low-grade glioma
Meningioma
Sarcoma
Jim chen.jpeg
 James L. Chen, MD, MS
Columbus, OH
LinkedIn 		Ewing's sarcoma
Gastrointestinal stromal tumor
Osteosarcoma
Sarcoma (other types)
Thoracic Oncology
TravisOsterman.jpg
 Travis Osterman, DO, MS
Nashville, TN
Twitter: TravisOsterman
LinkedIn 		Esophageal cancer
Mesothelioma
Non-small cell lung cancer
Small cell lung cancer
Thymoma
Myeloproliferative Neoplasms and Myelodysplastic Syndromes
Sanjay mohan.png
 Sanjay R. Mohan, MD, MSCI
Nashville, TN 		Chronic myelogenous leukemia
Chronic myelomonocytic leukemia
Essential thrombocythemia
Hypereosinophilic syndrome
Myelodysplastic syndrome (MDS)
Myelofibrosis
Polycythemia vera
Systemic mastocytosis
Plasma Cell Dyscrasias
Headshot Cowan.jpg
 Andrew J. Cowan, MD
Seattle, WA
LinkedIn 		Multiple myeloma
Light-chain (AL) amyloidosis
Page editor: Samuel M. Rubinstein, MD (Nashville, TN)
Plasma cell leukemia
POEMS
Transplant
Arichall 400x400.jpg
 Aric C. Hall, MD
Madison, WI
Twitter: AricHall1 		Stem cell mobilization
Allogeneic HSCT
Autologous HSCT
Graft versus host disease (GVHD)
Classical Hematology
Shruti.jpg
 Shruti Chaturvedi, MD, MSCI
Baltimore, MD
LinkedIn 		Aplastic anemia
Atypical hemolytic-uremic syndrome (aHUS)
Autoimmune cytopenias
Autoimmune thrombocytopenic purpura (ITP)
Coagulopathies
Cold agglutinin disease
Tillman Benjamin-2.jpg
 Benjamin Tillman, MD
Nashville, TN 		Hemophagocytic lymphohistiocytosis (HLH)
Paroxysmal nocturnal hemoglobinuria (PNH)
Sickle cell anemia
Thrombotic thrombocytopenic purpura (TTP)
Venous thromboembolism (VTE)
Retrieved from "https://hemonc.org/w/index.php?title=Editorial_Board&oldid=22304"